Evidence map›Paper›PMID 36964823›Full record

ArticleNeurochemical research2023

Cannabidiol Recovers Dopaminergic Neuronal Damage Induced by Reserpine or α-synuclein in Caenorhabditis elegans.

Erika da Cruz Guedes, Adolfo Garcia Erustes, Anderson H F F Leão, César Alves Carneiro, Vanessa C Abílio, Antonio W Zuardi, Jaime Eduardo C Hallak, José Alexandre Crippa, Claudia Bincoletto, Soraya S Smaili and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Erika da Cruz GuedesDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Três de Maio Street, 100, São Paulo, SP, 04044-020, Brazil.
Adolfo Garcia ErustesDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Três de Maio Street, 100, São Paulo, SP, 04044-020, Brazil.
Anderson H F F LeãoDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Três de Maio Street, 100, São Paulo, SP, 04044-020, Brazil.
César Alves CarneiroDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Três de Maio Street, 100, São Paulo, SP, 04044-020, Brazil.
Vanessa C AbílioDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Três de Maio Street, 100, São Paulo, SP, 04044-020, Brazil.
Antonio W ZuardiNational Institute for Translational Medicine (INCT-TM, CNPq), Ribeirão Preto, Brazil.
Jaime Eduardo C HallakNational Institute for Translational Medicine (INCT-TM, CNPq), Ribeirão Preto, Brazil.
José Alexandre CrippaNational Institute for Translational Medicine (INCT-TM, CNPq), Ribeirão Preto, Brazil.
Claudia BincolettoDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Três de Maio Street, 100, São Paulo, SP, 04044-020, Brazil.
Soraya S SmailiDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Três de Maio Street, 100, São Paulo, SP, 04044-020, Brazil.
Patrícia ReckziegelDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Gustavo J S PereiraDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Três de Maio Street, 100, São Paulo, SP, 04044-020, Brazil. gustavo.pereira@unifesp.br.
Universidade Federal de São Paulo · BRUniversidade de Ribeirão Preto · BRUniversidade de São Paulo · BRNational Council for Scientific and Technological Development · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/10863-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2019/02821-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/08840-1
6 · The paper itself

Abstract

Progressive neurodegenerative disorders such as Parkinson Disease (PD) lack curative or long-term treatments. At the same time, the increase of the worldwide elderly population and, consequently, the extension in the prevalence of age-related diseases have promoted research interest in neurodegenerative disorders. Caenorhabditis elegans is a free-living nematode widely used as an animal model in studies of human diseases. Here we evaluated cannabidiol (CBD) as a possible neuroprotective compound in PD using the C. elegans models exposed to reserpine. Our results demonstrated that CBD reversed the reserpine-induced locomotor alterations and this response was independent of the NPR-19 receptors, an orthologous receptor for central cannabinoid receptor type 1. Morphological alterations of cephalic sensilla (CEP) dopaminergic neurons indicated that CBD also protects neurons from reserpine-induced degeneration. That is, CBD attenuates the reserpine-induced increase of worms with shrunken soma and dendrites loss, increasing the number of worms with intact CEP neurons. Finally, we found that CBD also reduced ROS formation and α-syn protein accumulation in mutant worms. Our findings collectively provide new evidence that CBD acts as neuroprotector in dopaminergic neurons, reducing neurotoxicity and α-syn accumulation highlighting its potential in the treatment of PD.

Indexed as

Caenorhabditis elegans ProteinsCannabidiolNeurodegenerative DiseasesNeuroprotective AgentsParkinson DiseaseAgedalpha-SynucleinAnimalsAnimals, Genetically ModifiedCaenorhabditis elegansDisease Models, AnimalDopaminergic NeuronsHumansReceptors, G-Protein-CoupledReserpinealpha-SynucleinCaenorhabditis elegans ProteinsCannabidiolNeuroprotective AgentsNPR-19 protein, C elegansReceptors, G-Protein-CoupledReserpineCaenorhabditis elegansCannabidiolParkinson Disease

Identifiers

PMID36964823
OpenAlexW4360942100

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.